Presented at MAD-ID by Mohammed Al Musawa, PharmD, BCIDP, the study found lower clinical success with imipenem-cilastatin-relebactam in obese patients, raising questions about dosing strategies.
Mohammed Al Musawa, PharmD, BCIDP
Advertisement
Postdoctoral Fellow at Wayne State University
Articles by Mohammed Al Musawa, PharmD, BCIDP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
New Data Highlight Adult Pneumococcal Serotypes with Greater Antibiotic Resistance and Disease Burden Covered by Merck’s Vaccine
2
Developing a COVID-19 Vaccine Alternative
3
Oral Carbapenem Tebipenem HBr Demonstrates Non-Inferiority to IV Therapy in Phase III PIVOT-PO Trial
4
Generic Lenacapavir Could Cost as Little as $25 Per Person Annually
5
